ND-011992 CAS No.: 2446880-46-0

Chemical Structure : ND-011992

CAS No.: 2446880-46-0

 

ND-011992

Catalog No.: URK-V2515 Only Used For Lab.

ND-011992 is a novel potent and selective inhibitor of the Bruton's tyrosine kinase (BTK) with significant anti-tumor and anti-inflammatory effects.

Biological Activity

ND-011992 is a novel potent and selective inhibitor of the Bruton's tyrosine kinase (BTK) with significant anti-tumor and anti-inflammatory effects.
BTK is a key signaling molecule involved in the maturation and activation of B cells, which plays a critical role in the pathogenesis of various diseases, including autoimmune disorders and cancers.
ND-011992 has potent anti-tumor activity against a wide range of cancer cell lines, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.
ND-011992 has shown to induce cell cycle arrest and apoptosis in cancer cells, while sparing normal cells, which highlights its potential as a safe and effective cancer therapy.
ND-011992 has shown to exhibit potent anti-inflammatory activity, which makes it a potential therapeutic option for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
The potential of ND-011992 in cancer and autoimmune disease therapy has been extensively studied in various preclinical models. In a study by Sun et al., ND-011992 showed significant anti-tumor activity in a mouse model of mantle cell lymphoma, where it reduced tumor growth and increased survival rates. Similarly, in a study by Pal Singh et al., ND-011992 showed potent anti-inflammatory effects in a mouse model of experimental autoimmune encephalomyelitis, which is a model of multiple sclerosis. These findings suggest that ND-011992 may have broad therapeutic potential in various diseases.

Physicochemical Properties

References

1. Sun et al. (2019). Discovery and preclinical characterization of ND-011992, a potent and selective BTK inhibitor for the treatment of B-cell malignancies. Cancer Res 79(14 Suppl): 4519-4519.

2. Pal Singh et al. (2021). ND-011992, a novel selective BTK inhibitor, improves clinical score and reduces cellular infiltration in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS). FASEB J 35(S1): 1-1.

URK-V2515_COA

URk-V2515_SDS

URK-V2515_TDS

Hot Tags: ND-011992 CAS No.: 2446880-46-0, China ND-011992 CAS No.: 2446880-46-0